Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Novavax Booster Vaccines in Adults ≥ 50
NCT05925127Phase 3Completed
- Sponsor
- Novavax
- Start
- Oct 2023
- Primary completion
- May 2024
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Nuvaxovid XBB.1.5 in coronavirus disease 2019 (COVID-19), sponsored by Novavax. Started Oct 2023; status: completed.
02
Drugs
Nuvaxovid XBB.1.5
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05925127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05925127.